Use of sibutramine and other noradrenergic and
serotonergic drugs in the management of obesity
by
Ryan DH.
Pennington Biomedical Research Center,
Baton Rouge, LA, USA.
ryandh@pbrc.edu
Endocrine 2000 Oct;13(2):193-9

ABSTRACT

Drugs that act through noradrenergic and serotonergic mechanisms have historically served as the mainstays of pharmacologic treatments for obesity. This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpropanolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets.

Fen/Phen
Serotonin
Fluoxetine
Sibutramine
Noradrenaline
Amphetamines
SSRIs and SNRIs
Sibutramine abuse
New slimming drugs
Sibutramine compared
Sibutramine and obesity
Sibutramine for binge-eaters
Sibutramine v dexfenfluramine
Sibutramine as an antidepressant
Sibutramine (Meridia): clinical use
Sibutramine (Meridia): clinical pharmacology
Dual-action antidepressants and slimming-drugs

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Superhappiness?
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family